Last month’s American Society of Clinical Oncology (ASCO) meeting kicked off with a presentation from Professor Ruth Plummer, a medical oncologist from Newcastle in the UK who, in 2003, was
This week’s news has been dominated by the downfall of ‘rock star’ investment manager Neil Woodford, who has made his name by championing many businesses in UK biotech.
Failed clinical trials can be fatal for small biotechs that don’t have the backing of big pharma, and even having to alter plans can be prohibitively costly.
Massachusetts holding company ElevateBio has launched with $150m in initial funding from a range of investors on a mission to build a portfolio of cell and gene therapy companies.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
